3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
2
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Etoposide
154
Carboplatin
142
Cisplatin
104
Topotecan
74
durvalumab
48
atezolizumab
46
Irinotecan
44
pembrolizumab
39
Paclitaxel
34
Nivolumab
33
Radiotherapy
29
anlotinib
23
PM 01183
22
Gemcitabine
21
Drug Therapy
20
apatinib
19
Ipilimumab
18
Docetaxel
17
Temozolomide
16
Platinum
16
Radiosurgery
15
Pemetrexed
14
toripalimab
13
tislelizumab
13
olaparib
13
Bevacizumab
13
amrubicin
11
Magnetic Resonance Spectroscopy
11
Cyclophosphamide
11
rovalpituzumab tesirine
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Interventional
×
Small Cell Lung Carcinoma
×
RRx-001
×
Clear all
NCT05566041
2024-10-31
REPLATINUM
EpicentRx, Inc.
Phase 3
Active not recruiting
292 enrolled
NCT03699956
2024-03-26
REPLATINUM
EpicentRx, Inc.
Phase 3
Terminated
18 enrolled